Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib
NCT05265988
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma Prostate
Interventions
DRUG:
Cabozantinib
Sponsor
Alfredo Berruti